MX2024006746A - Métodos de uso de agentes de interleucina-2. - Google Patents

Métodos de uso de agentes de interleucina-2.

Info

Publication number
MX2024006746A
MX2024006746A MX2024006746A MX2024006746A MX2024006746A MX 2024006746 A MX2024006746 A MX 2024006746A MX 2024006746 A MX2024006746 A MX 2024006746A MX 2024006746 A MX2024006746 A MX 2024006746A MX 2024006746 A MX2024006746 A MX 2024006746A
Authority
MX
Mexico
Prior art keywords
methods
interleukin
agents
transplant rejection
treat
Prior art date
Application number
MX2024006746A
Other languages
English (en)
Spanish (es)
Inventor
Gregory Babcock
Wayne Hancock
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of MX2024006746A publication Critical patent/MX2024006746A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024006746A 2021-12-01 2022-12-01 Métodos de uso de agentes de interleucina-2. MX2024006746A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284978P 2021-12-01 2021-12-01
US202263348201P 2022-06-02 2022-06-02
PCT/US2022/080728 WO2023102463A1 (en) 2021-12-01 2022-12-01 Methods of using interleukin-2 agents

Publications (1)

Publication Number Publication Date
MX2024006746A true MX2024006746A (es) 2024-08-09

Family

ID=84981477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006746A MX2024006746A (es) 2021-12-01 2022-12-01 Métodos de uso de agentes de interleucina-2.

Country Status (10)

Country Link
US (1) US12642840B2 (enExample)
EP (1) EP4440598A1 (enExample)
JP (1) JP2024543209A (enExample)
KR (1) KR20250169356A (enExample)
CN (1) CN120131911A (enExample)
AU (1) AU2022399832A1 (enExample)
CA (1) CA3238574A1 (enExample)
MX (1) MX2024006746A (enExample)
TW (1) TW202333772A (enExample)
WO (1) WO2023102463A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
US20260028384A1 (en) * 2024-04-17 2026-01-29 Visterra, Inc. Use of il-2 variant for treating kidney transplant rejection
CN119638850B (zh) * 2024-11-07 2026-07-31 浙江大学 双特异性细胞因子融合蛋白及其应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4908433A (en) 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0262802A3 (en) 1986-09-01 1990-01-31 Takeda Chemical Industries, Ltd. Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5466447A (en) 1988-06-29 1995-11-14 Amgen Inc. Method for treating psoriasis
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
CA2100671C (en) 1991-02-27 1999-02-02 James S. Huston Serine rich peptide linkers
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
CA2456470A1 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
KR20070003934A (ko) 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
JP2009542592A (ja) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−2媒介性免疫応答の有効性を高める組成物および方法
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
KR100873651B1 (ko) 2008-08-21 2008-12-11 김광한 잔디 식재기
KR101094207B1 (ko) 2008-08-21 2011-12-14 연세대학교 산학협력단 T1―t2 이중방식 mri 조영제
KR100996532B1 (ko) 2008-08-22 2010-11-24 주식회사 엠아이텍 탄소나노튜브 기반 바이오센서에서 링커와 스페이서를 이용한 민감도 증가 방법
KR101111286B1 (ko) 2008-08-22 2012-03-14 한국생산기술연구원 발포체, 이 발포체의 제조장치, 이 발포체를 이용한 발포금속의 제조방법 및 발포금속 제조장치
WO2010021527A2 (ko) 2008-08-22 2010-02-25 Jung Tae Woo 영상에 포함된 객체를 색인하는 시스템 및 방법
CN102197027A (zh) 2008-08-22 2011-09-21 株式会社Lg化学 用于有机电子器件的材料以及使用所述材料的有机电子器件
WO2010021525A2 (en) 2008-08-22 2010-02-25 Lg Electronics Inc. A method for processing a web service in an nrt service and a broadcast receiver
WO2010021520A2 (ko) 2008-08-22 2010-02-25 엘지전자 주식회사 동기 채널 전송 방법
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
EP3443979B2 (en) 2011-03-11 2026-05-20 Assistance Publique - Hôpitaux De Paris IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
US9669071B2 (en) 2011-03-11 2017-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating T lymphocytes with IL-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
KR102493543B1 (ko) 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
AU2016246152A1 (en) 2015-04-10 2017-11-02 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
RU2611685C2 (ru) 2015-07-20 2017-02-28 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20240115933A (ko) 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US20210277085A1 (en) 2017-05-24 2021-09-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US20200306301A1 (en) * 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
IL320863A (en) 2017-10-02 2025-07-01 Visterra Inc Antibodies to CD138 and their uses
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
KR20240115352A (ko) 2017-12-06 2024-07-25 팬디온 오퍼레이션스, 인코포레이티드 Il-2 뮤테인 및 그 용도
EP3720871A4 (en) 2017-12-06 2021-09-15 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたil-2 fc融合タンパク質
US12522640B2 (en) 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
WO2022159590A1 (en) 2021-01-20 2022-07-28 Visterra, Inc. Interleukin-2 mutants and uses thereof
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
CA3243493A1 (en) 2022-02-11 2023-08-17 Visterra, Inc. INTERLEUKIN-2 MUTEINS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Also Published As

Publication number Publication date
CN120131911A (zh) 2025-06-13
US20240041981A1 (en) 2024-02-08
CA3238574A1 (en) 2023-06-08
US12642840B2 (en) 2026-06-02
WO2023102463A1 (en) 2023-06-08
EP4440598A1 (en) 2024-10-09
AU2022399832A1 (en) 2024-06-06
KR20250169356A (ko) 2025-12-03
TW202333772A (zh) 2023-09-01
JP2024543209A (ja) 2024-11-19

Similar Documents

Publication Publication Date Title
MY209474A (en) Il-2 conjugates and methods of use to treat autoimmune diseases
EA202091809A1 (ru) Агонистические антитела против pd-1 и их применение
MX2022011676A (es) Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
EP4442278A3 (en) Humanized antibodies against c-kit
PH12020551019A1 (en) IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2019014023A (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
EA202091219A1 (ru) Культивирование плаценты с целью выделения экзосом
BR112018076306A2 (pt) composições e métodos para a supressão de células cd117+
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
JOP20220036A1 (ar) ميوتينات إنترلوكين-2 لتمديد الخلايا التائية التنظيمية
MX2022012471A (es) Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
MX2018011162A (es) Metodos de purificacion de colageno 7.
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
WO2018220489A3 (en) METHODS OF OBTAINING CELLS FROM HUMAN OMBILICAL POST-PARTUM CORDON ARTERIAL TISSUE
ZA202100888B (en) Methods of preparing personalized blood vessels
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
MX2023006651A (es) Tratamiento de la hemofilia con fitusirán.
WO2021101273A3 (ko) 조절 t 세포 배양용 조성물 및 이의 용도
MX2023005063A (es) Proteinas de fusion sap fc y metodos de uso.
EA201992343A1 (ru) Замещенные бициклические гетероциклические соединения в качестве ингибиторов надфн-оксидазы
ZA202204386B (en) Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
ECSP22019177A (es) Proteínas de fusión nkg2d y sus usos
JOP20230034A1 (ar) مثبطات إفراز البروتين